Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers

BACKGROUND: Xeroderma pigmentosum (XP), a rare disease with defects in DNA repair genes, has >1,000-fold increased risk of ultraviolet-induced skin cancers. Immune checkpoint inhibitors (ICIs) are used for treating cancers with large numbers of mutations but may also promote adverse events (AEs)....

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Elvelyn R., Tamura, Deborah, Khan, Sikandar G., Momen, Sophie, Fassihi, Hiva, Sarkany, Robert, DiGiovanna, John J., Kraemer, Kenneth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634243/
https://www.ncbi.nlm.nih.gov/pubmed/37954081
http://dx.doi.org/10.3389/fonc.2023.1282823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634243/
https://www.ncbi.nlm.nih.gov/pubmed/37954081
http://dx.doi.org/10.3389/fonc.2023.1282823

Ejemplares similares